ProCE Banner Activity

An Expert Cardiologist’s Insights on Addressing Residual Inflammatory Risk in Patients With ASCVD and CKD

Clinical Thought

In this commentary, read expert insights from a cardiologist about current and future therapies designed to target residual inflammatory risk in patients with ASCVD and CKD.

Released: September 04, 2024

Expiration: September 03, 2025

Share

Faculty

Erin Michos

Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Professor of Medicine
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co Center-Director, IMPACT Center at JHU
(Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials)
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC in collaboration with American Kidney Fund.

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

American Kidney Fund

ProCE Banner

Disclosure

Primary Author

Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Professor of Medicine
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co Center-Director, IMPACT Center at JHU
(Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials)
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC: consultant/advisor/speaker: Amgen, Arrowhead, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Ionis, Lilly, Medtronic, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer.